Kornimate/medical-research-clean huggingface dataset:
navigated brain stimulation in diagnosis of minimally conscious state

Conditions: Vegetative State; Stroke; Brain Injury

Summary: it has already been demonstrated that mental imagining of the complex motor act, such as limb lifting, can evoke the activation of the involved motor centres even if it doesn't result in movement due to paresis. aim of the study: using the navigated brain stimulation system create a new diagnostic model for the differential diagnostics between the vegetative state and the minimally conscious state. if the investigators could get from patient the efferent motor response after a verbal command, his level of conscious should not be defined less than the minimally conscious state.


Eligibility criteria:
inclusion criteria: * diagnosed vegetative state * age 20-85 exclusion criteria: * oncological history * cardiac pacemakers and other metal implants * modified ashford scale scores 3 and more * predisposing disease with motor neurologic impairment

Keywords: diagnosed vegetative state after stroke or traumatic brain injury
diet and activity in cerebral palsy

Conditions: Cerebral Palsy

Summary: this study aims to fill a gap in the literature, identify relevant clinical measures, and provide insight into the independent modifiable risk factors of obesity in the cp population with the long-term goal of improving screening, management and prevention of obesity in this at-risk and underserved population.


Eligibility criteria:
inclusion criteria: * adolescent and adult subjects 16-89 years with a diagnosis of cerebral palsy exclusion criteria: * concurrent severe neurologic or other medical diagnosis that is likely to be contributing to the subject's functional impairment, as determined by the study investigators. for example, associated spinal cord injury. * subjects with major limb amputations * pregnant or lactating females

Keywords: cerebral palsy adolescents adults diet activity metabolic syndrome
efficacy and safety of an2898 and an2728 topical ointments to treat mild-to-moderate atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: the purpose of this study is to determine whether an2898 and an2728 ointments are safe and effective treatments for mild-to-moderate atopic dermatitis (ad).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of atopic dermatitis that has been clinically stable for ≥1 month * total body surface area (bsa) of atopic dermatitis involvement ≤35%, excluding involvement of the face, scalp, and groin * presence of two (2) comparable target lesions * willing and able to apply study medications as directed, comply with study instructions, and commit to attending all visits * females of childbearing potential must use at least one highly effective method of birth control. males with partners of childbearing potential should inform them of their participation in this clinical study and use highly effective methods of birth control during the study. exclusion criteria: * concurrent or recent use of certain topical or systemic medications or phototherapy without a sufficient washout period * active or potentially recurrent dermatologic condition other than atopic dermatitis in the target lesion area that may confound evaluation * significant confounding conditions as assessed by study doctor * history or evidence of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis) * participated in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study * pregnancy or lactation

Keywords: atopic dermatitis
clinical evaluation of two multifocal contact lenses

Conditions: Presbyopia

Summary: the aim of this study is to evaluate the patient subjective experiences of the monthly multifocal lens when compared to the daily disposable multifocal lens after 15 minutes of daily wear.

this is a single-blind, interventional, prospective, direct refit, bilateral wear study.

Eligibility criteria:
inclusion criteria: * is at least 42 years of age and has full legal capacity to volunteer. * has read and signed an information consent letter. * self-reports having a full eye examination in the previous two years. * anticipates being able to wear the study lenses for at least 8 hours a day, 5 days a week. * is willing and able to follow instructions and maintain the appointment schedule. * habitually wears multifocal soft contact lenses, or sphere lenses for monovision, or sphere lenses for monovision, or sphere lenses for distance vision correction and use spectacles for near vision correction, for the past 3 months minimum. * has refractive astigmatism no higher than -0.75dc. * is presbyopic and requires a reading addition of at least +0.75d and no more than +2.50d. * can be fit and achieve binocular distance vision of at least 20/30 snellen (or +0.20 logmar) which participants also deem to be 'acceptable', with the available study lens parameters (powers +4.00 to -6.00ds). exclusion criteria: * is participating in any concurrent clinical or research study. * has any known active ocular disease and/or infection that contraindicates contact lens wear. * has a systemic condition that in the opinion of the investigator may affect a study outcome variable. * is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable. * has known sensitivity to the diagnostic sodium fluorescein used in the study. * self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment. * has undergone refractive error surgery or intraocular surgery.
efficacy of motilitone on gastric emptying in patients with functional dyspepsia: evaluation using mri method

Conditions: Dyspepsia

Summary: functional dyspepsia (fd) is a disorder characterized by chronic or recurrent upper abdominal pain or discomfort in the absence of a specific structural cause.1 several mechanisms have been suggested to underlie dyspeptic symptoms. in a barostat study by tack et al.2, impaired gastric accommodation to a meal was found in 40% of patients with fd, and this abnormality was associated with early satiety. delayed gastric emptying (ge) was also found in almost 40% of patients with fd, and was associated with the symptoms of postprandial fullness, vomiting and early satiety.3-5 improving gastric accommodation and prokinetic effect seem to be an attractive physiological target in patients with fd. motilitone (dong-a st, yongin, korea) is a new herbal drug that was launched in december 2011 in korea for treating patients with fd. it has multiple mechanisms of action such as fundus relaxation, visceral analgesia and prokinetic effects.6 the current study aims to evaluate effects of motilitone on gastric emptying and accommodation after a meal in patients with fd using three-dimensional gastric volume measurements by magnetic resonance imaging (mri). patients are randomly allocated to receive either motilitone 90 mg daily, motilitone 180 mg daily or placebo in a double blinded manner. after 2 weeks of treatment, patients undergo gastric mri. the primary endpoint is gastric emptying rate. the secondary endpoints are gastric accommodation and symptom improvement.

same as above

Eligibility criteria:
inclusion criteria: 1. 20 and 70 years of age 2. diagnosed of functional dyspepsia patients by rome iii diagnostic criteria 3. symptom scores three-point by 8 kinds of symptoms on ndi-k table 4. signed written informed consent. exclusion criteria: 1. any functional gi diease 2. previous abdominal surgery 3. pregnancy or lactation 4. other conditions likely to interfere with study procedures. as judged by the investigator 5. allergic history to motilitone 6. contraindications to mri 7. significant cardiopulmonary disease 8. significant renal(serum creatinine level≥1.5 x the upper normal limit) or liver (ast or alt≥2.5xuln)disease 9. can not be stopped taking medications that gastric motility booster and antacid prior to the start of the study 10. uncontrollable diabetes mellitus (hba1c\>7%) 11. any malignancies within 5 years prior to the start of the study

Keywords: accommodation, emptying,motilitone
combined drug therapy in lateral fragility fractures of the femur

Conditions: Femur Fracture

Summary: it was conducted a prospective study with a series of 50 patients treated by intramedullary nail using clodronic acid and vitamin d (study group including 25 patients) and patients with the same fractures treated with vitamin d alone (control group including 25 patients). one independent observer performed clinical, biochemical and functional evaluations at t0 (1st day post-surgery) and at t1 (12 months later) biochemical markers (serum calcium level, serum phosphate level, pth (parathormone), vitamin d, serum c-terminal telopeptide), vas (visual analogic scale) and hhs (harris hip score) score, and femur densitometric views were administered at each evaluation.


Eligibility criteria:
inclusion criteria: * femur fractures type 31-a1, a2, (muller me, nazarian s, kock p et al.); * age 60 - 85 years; * co-operative patients; * body mass index (bmi) \< 30 kg/m²; * patients treated by intramedullary nailing surgery (pfna synthes®); * patients with osteoporosis disease if t-score\< -2,5; exclusion criteria: * patients with heart, kidney, neurological diseases; * patients with metabolic and systemic disease (rheumatoid arthritis, diabetes mellitus); * previous surgery or severe osteoarthritis of lower limbs; * specific drugs treatments such as anticoagulants or psychiatric drugs.

Keywords: fragility lateral femoral fractures bisphosphonates clodronic acid bone density
effect of strategy for blood pressure control on cerebral oxygen balance during aortic coarctation repair: a randomized study

Conditions: Cerebral Oxygenation

Summary: in a prospective and randomized study protocol, three different blood pressure regulating agents (nitroprusside, nitroglycerine, sevoflurane) will be compared concerning their effect on the cerebral oxygen balance between both hemispheres during aortic coarctation repair. cerebral and somatic saturation will be monitored non-invasively and continuously via optical sensors applied to the right and left forehead and the somatic regions. arterial blood pressure, central venous pressure, heart rate and systemic saturation will be recorded continuously. intermittently, arterial and venous blood gas analysis will be performed at 6 definite time intervals. the study ends at the end of the operation.


Eligibility criteria:
inclusion criteria: * all neonates and infants * aged 0-18 year * with aortic coarctation requiring surgical correction without the additional use of cardiopulmonary bypass will be included. exclusion criteria: * all patients with an associated cardiac effect are excluded.
defining response criteria for pet scans for people with neuroendocrine tumors

Conditions: Neuroendocrine Tumors

Summary: people with neuroendocrine cancer typically have imaging scans before and after treatment, including positron emission tomography (pet) scans. the scans are analyzed using a set of criteria that describes how the disease has responded to treatment. the purpose of this study is to establish new criteria for doctors to use when evaluating these pet scans. researchers are testing whether these new criteria are useful for predicting whether a person's cancer gets better, gets worse, or stays the same. researchers will also compare these new criteria to the current standard criteria for evaluating imaging scans.


Eligibility criteria:
subjects affected by histologically proven, somatostatin-receptor positive, metastatic or inoperable well-differentiated g1, g2 or g3 neuroendocrine tumors (nets) candidate to receive prrt with 177lu-dotatate per standard of care. inclusion criteria: 1. histologically proven or cytologically confirmed, metastatic or inoperable nets 2. measurable disease as defined by recist 1.1. 3. overexpression of somatostatin receptors of the target lesions at somatostatin receptor imaging (68ga-dotatate or 64cu-dotatate pet/ct) with suv of lesions greater than normal liver at least in 1 metastasis. exclusion criteria: 1. neuroendocrine carcinoma), small and large cell type; mixed neuroendocrine-nonneuroendocrine neoplasm (minen). 2. presence of somatostatin receptor negative lesions.

Keywords: pet scan ct scan 24-100
the safety and effectiveness of warfarin and dabigatran prescribed in the non-valvular atrial fibrillation population with dod healthcare coverage

Conditions: Atrial Fibrillation

Summary: the objective is to assess the safety and effectiveness of new dabigatran and warfarin patients diagnosed with nvaf in the us dod population.

study design: retrospective

Eligibility criteria:
inclusion criteria: * patients must be continuously enrolled in a health plan during the pre-index period; * patients must have at least one inpatient, or one physician office visit, emergency room visit with a diagnosis of af (icd-9-cm diagnosis code: 427.31in any position) on the index date or during the pre-index period; * patients must have a prescription for dabigatran or warfarin (this first prescription will be the index date); * patients must be treatment naive from all oac use prior to first dabigatran or warfarin prescription; * aged 18-89 on the index date; exclusion criteria: * patients with valvular procedures related to the baseline af diagnosis will be excluded; * patients with transient causes of af such as hyperthyroidism, any cardiac surgery, pericarditis, mycoarditis, pulmonary embolism within 3 months prior to their first diagnosis of af;
a study to assess som230 in patients with pituitary cushing's disease

Conditions: Cushing's Syndrome

Summary: the study treatment period is 15 days in length and includes patients with pituitary cushing's disease who are candidates for surgical intervention as well as and patients who have recurrent cushing's post operatively.


Eligibility criteria:
inclusion criteria: * patients with pituitary cushing's disease within the two months prior to study entry * patients for whom written informed consent to participate in the study has been obtained * female patients of child bearing potential who have not undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation must agree to use barrier contraception throughout the course of the study, and for one month after the study has ended exclusion criteria: * female patients who are pregnant or lactating * patients who have been previously treated with certain medications may be required to be without certain medications prior to entering the study * poorly controlled diabetes mellitus as indicated by the presence of ketoacidosis or hgba1c \> 10 * patients who have congestive heart failure, unstable angina, cardiac arrhythmia or history of acute mi less than one year prior to the study entry or clinically significant impairment in cardiovascular function (e.g. blood pressure of 190/100mmhg or greater) * patients with chronic liver disease * patients with clotting disorders or abnormal blood counts * history of immuno-compromise, including a positive hiv test result * patients with active gall bladder disease * patients who have participated in any clinical investigation with an investigational drug within 1 month prior to dosing * patients with active malignant disease (with the exception of basal cell carcinoma or carcinoma in situ of the cervix)
efficacy of the application of xylocaine impregnated compress in reducing per-procedural pain during ultrasound-guided infiltration of trigger finger

Conditions: Trigger Finger

Summary: the purpose of this study is to assess the efficacy of xylocaine impregnated compress in reducing per-procedural pain during ultrasound-guided infiltration of trigger finger

trigger finger ultrasound-guided infiltrations are frequent and painful invasive procedures. however, there is no current recommendation for per-procedural pain management, and in the majority of cases, infiltration is performed without prior skin anesthesia. xylocaine patches are of controversial efficacy in pain acute management. in current practice, they are not prescribed in advance and they are not well adapted to the topography of the finger. on the other hand, a recent study showed the interest of administering lidocaine 2% by j-tip, a needle-free injection technique not available in france, before infiltration of trigger finger. the investigators hypothesize that an impregnated compress in xylocaine 20 mg/ml injectable solution, applied 15 minutes before the procedure, would reduce per-procedural pain.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older * trigger finger (clinically defined by painful difficulty or protrusion when extending the finger) with an ultrasound-guided infiltration of cortisone derivatives indication. * written consent * affiliation to a social security system * prior medical examination exclusion criteria: * neurological conditions affecting the hand other than carpal tunnel syndrome * intra-articular infiltration of the hand or the wrist ≤ 2 months * allergy to xylocaine * contraindication to xylocaine or cortisone derivatives * cognitive or behavioral disorders that make assessment impossible * persons referred to in articles l 1121-5; 6; 8; 9 of the public health code (protected adults, under guardianship or curatorship, etc) * pregnancy and breastfeeding; absence of contraceptive method for women of childbearing age * participant unable to speak, read and write french

Keywords: trigger finger xylocaine
ktp (potassium-titanyl-phosphate) laser versus tur-p (transurethral resection of prostate)

Conditions: BPH (Benign Prostatic Hyperplasia)

Summary: the purpose of this study is to compare safety and efficacy of green light pvp (photoselective vaporisation of the prostate) compared to tur-p.


Eligibility criteria:
inclusion criteria: * men undergoing surgery for bph exclusion criteria: * previous prostate surgery * carcinoma of the prostate * neurogenic bladder * bladder carcinoma
immuno-stimulation with maraviroc combined to antiretroviral therapy in advanced late diagnosed hiv-1 infected patients

Conditions: HIV-1 Infection; AIDS

Summary: the objective of the optimal study is to demonstrate that the adjunction of maraviroc to a combination of antiretroviral therapy in naive and late diagnosed hiv-1 infected patients counts may accelerate the kinetics of immune restoration and decrease the risk of disease progression and death. it is a randomized, versus placebo, double-blind trial, conducted in france, spain and italy.


Eligibility criteria:
inclusion criteria: * confirmed hiv-1 infection (elisa and western blot tests positive) * cd4+ t lymphocytes below or equal 200/mm³ or previous aids-defining-illness at diagnosis * patient naïve from any antiretroviral * in women, use of a contraceptive method, and lack of actual pregnancy * patients with a coverage from social health * after informed consent exclusion criteria: * current pregnancy, lack of contraceptive method, breast-feeding * current active tuberculosis (either suspected, diagnosed) * ongoing malignancies except cutaneous kaposi's sarcoma. patients with a previous cancer considered as cured for at least 6 months could be included in the study * current or previous severe cardiac failure, chronic respiratory disease, renal or liver insufficiency; any life-threatening organ failure * cognitive impairment, psychiatric disorders, severe depressive affects, unadapted behavior * use of cytostatic drugs, immunosuppressive agents, steroids * pmn (polymorphonuclear neutrophil) below 750/mm³, platelets below 50,000/mm³, haemoglobin below 10 g/dl; asat (aspartate aminotransferase), alat (alanine aminotransferase) or bilirubin over 2.5 uln; lipase over 2 uln (upper limit of normal), serum creatinine over 1.5 uln; proteinuria over 1g/l; inr (international normalized ratio) abnormal * current or previous, during the 3 last months, use of immunomodulatory agents (g-csf (granulocyte colony stimulating factor), il-2 (interleukin-2), gm-csf (granulocyte macrophage colony stimulating factor), interferons, pentoxifylline) * hypersensitivity to peanut and /or soy products

Keywords: late diagnosed hiv-1 infected patients aids-defining events immune restoration
safety and effectiveness of visipaque 320mg-i/ml for use in contrast-enhanced ct angiography of arteries of the heart

Conditions: Coronary Artery Disease

Summary: ct (computed tomography) angiography (cta) is an examination similar to a cat scan that uses x-rays and a contrast medium (also called dye) to visualize blood flow in arteries and veins throughout the body visipaque™ will be given through a vein in the arm before having the cta scan of the heart arteries. the pictures it produces of the heart and its blood vessels will be reviewed and compared to those obtained during the catheter-based coronary angiography to see if the cta shows the same blockages.


Eligibility criteria:
inclusion criteria: * subject is ≥18 years old. * subject must have been referred for an elective coronary angiography for one of several specified conditions. exclusion criteria: * the subject has impaired renal function with a serum creatinine level ≥1.7 mg/dl (150 μmol/l). if the institution's practising guideline(s) regarding the serum creatinine limits for receiving radiologic contrast medium are lower than 1.7 mg/dl (150 μmol/l), the investigator should follow the practising guideline(s) of their institution. * subject has a known allergy to iodinated contrast agent * subject has atrial fibrillation/flutter or any irregular heart rhythm considered to interfere with temporal acquisition of cardiac ct images. * the subject's resting heart rate is 66-100 bpm and β-blocker therapy is contraindicated. * use of nitroglycerin is contraindicated. * subject has had a prior cabg procedure. * subject has a metal cardiac stent in place or artificial heart valve(s). * subject has had a prior pacemaker or internal defibrillator lead implantation. subject must agree to discontinue metformin day of and for 48 hours after the cta procedure.

Keywords: coronary angiography x-ray cad